U. Scheuring

Ying Cheng, K. Syrigos, N. Rizvi, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.

T. Lipp, C. Schoch, H. Gschaidmeier, 2004, Blood.

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

H. Gschaidmeier, O. Ottmann, B. Wassmann, 2003, Leukemia.

Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

M. Lübbert, H. Gschaidmeier, O. Ottmann, 2003, Leukemia.

GliPR1 knockdown by RNA interference exerts anti‐glioma effects in vitro and in vivo

G. Schackert, A. Temme, U. Scheuring, 2021, Journal of Neuro-Oncology.

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

H. Gschaidmeier, O. Ottmann, B. Wassmann, 2002, Leukemia.

Inhibition of X4-tropic HIV type 1 replication by knockdown of the cellular protein LEREPO4.

U. Dietrich, O. Ottmann, D. Hoelzer, 2010, AIDS research and human retroviruses.

Endoplasmic reticulum protein GliPR1 regulates G protein signaling and the cell cycle and is overexpressed in AML.

H. Klein, S. Koschmieder, O. Ottmann, 2013, Oncology reports.

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

W. Hofmann, M. Lübbert, H. Gschaidmeier, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005 .

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Edward S. Kim, N. Reinmuth, M. Ahn, 2020, JAMA oncology.

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

E. Helman, S. Peters, F. Liu, 2020, Clinical Cancer Research.

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

E. Thiel, C. Bartram, C. Pott, 2006, Blood.

Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination

J. Rockstroh, T. Sauerbruch, U. Spengler, 2003, Medical Microbiology and Immunology.

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.

N. Reinmuth, D. Planchard, R. Soo, 2020, Annals of Oncology.

Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).

N. Reinmuth, M. Ahn, F. Shepherd, 2021, Clinical lung cancer.

HIV-1 Infection Suppresses Expression of Host Cell Cycle-Associated Gene PDS5A

O. Ottmann, D. Hoelzer, G. Capalbo, 2011, Intervirology.

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

H. Gschaidmeier, O. Ottmann, B. Wassmann, 2003, Blood.

Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

M. Lübbert, H. Gschaidmeier, O. Ottmann, 2003, Leukemia.

Differential expression profiles of apoptosis-affecting genes in HIV-infected cell lines and patient T cells.

J. Corbeil, H. Sabzevari, A. Theofilopoulos, 1999, AIDS.

Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results

R. Bukowski, C. Szczylik, Thomas E. Hutson, 2007 .

Inhibition of HIV-1 replication by small interfering RNAs directed against Glioma Pathogenesis Related Protein (GliPR) expression

U. Dietrich, O. Ottmann, D. Hoelzer, 2010, Retrovirology.

OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

N. Reinmuth, M. Ahn, N. Rizvi, 2019, Journal of Thoracic Oncology.

Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.

Edward J. Kim, N. Reinmuth, M. Ahn, 2019, Clinical Trials.

Risk/MRD adapted GMALL trials in adult ALL.

C. Bartram, M. Kneba, D. Hoelzer, 2004, Annals of hematology.

Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study

W. Lehmacher, V. Dicken, S. Zaim, 2017, Acta radiologica.

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study.

N. Reinmuth, M. Ahn, F. Shepherd, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Characterization of ZC3H15 as a potential TRAF-2-interacting protein implicated in the NFκB pathway and overexpressed in AML.

H. Klein, S. Koschmieder, O. Ottmann, 2013, International journal of oncology.

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005, Blood.

Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.

Edward S. Kim, N. Reinmuth, M. Ahn, 2019, Journal of Clinical Oncology.

Early modifications of host cell gene expression induced by HIV‐1

J. Corbeil, A. Theofilopoulos, D. Mosier, 1998, AIDS.

Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.

N. Reinmuth, M. Ahn, F. Shepherd, 2019, Journal of Clinical Oncology.